Solos Endoscopy, Inc. Completes Capital Restructuring Initiative

BOSTON, Nov. 26, 2010 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has completed a capital restructuring initiative as part of a previously announced recapitalization plan in order to position itself for growth over the next twelve months. The restructuring involved a common stock consolidation that took effect November 24, 2010. As a result of this announcement, the stock symbol will be changed temporarily to SNDYD for a period of 20 business days after November 24, 2010.

The recapitalization plan allows Solos greater flexibility to utilize the assets of the Company in the future for corporate purposes; including raising capital, acquisitions or employee compensation, with limited dilution of existing stockholder voting rights.

"We believe our restructuring initiative represents a balanced approach to refining the Company's capital structure on behalf of our stockholders, while repositioning Solos for sustainable growth in earnings over the long- term," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.